Heena Sharma Blog

Drug firm Glenmark Pharmaceuticals on Monday said it has received tentative approval from the US health regulator for generic Dapagliflozin tablets used for treatment of type-2 diabetes. The product is a generic version of AstraZeneca AB's Farxiga tablets. "Glenmark Pharmaceuticals Inc USA has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Dapagliflozin tablets, 5 mg and 10 mg," Glenmark said in a filing to BSE. Citing IQVIA sales data for the 12 month period ending January 2020, the company said Farxiga tablets, brand and all available therapeutic equivalents in strengths of 5 mg and 10 mg, achieved annual sales of approximately $1.8 billion. Read More

While Type-2 diabetes is expected to rise by more than a fifth, from 406 million in 2018 to 511 million in 2030 globally, India along with China and the US will share over half of these high blood sugar cases , say researchers led by one of an Indian-origin, while asserting the need to improve access for the life saving insulin. The study, published in The Lancet Diabetes and Endocrinology journal, showed that China (130 million) followed by India (98 million), and the US (32 million) will constitute over half of Type-2 diabetics by 2030. As a result, the amount of insulin needed to effectively treat Type-2 diabetes will rise by more than 20 per cent worldwide over the next 12 years. Compared to current levels of insulin access, if universal global access was achieved (with a treatment target of HbA1c -- measure of blood glucose) seven per cent or lower, the number of people with Type-2 diabetes worldwide using insulin in 2030 would double from around 38 million (7.